Disc Medicine
IRON
91 hedge funds and large institutions have $934M invested in Disc Medicine in 2023 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 19 reducing their positions, and 18 closing their positions.
105% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 19
10% more capital invested
Capital invested by funds: $849M → $934M (+$85.2M)
1.55% more ownership
Funds ownership: 85.34% → 86.89% (+1.6%)
1% more funds holding
Funds holding: 90 → 91 (+1)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
56% less call options, than puts
Call options by funds: $4.42M | Put options by funds: $9.95M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$63.6M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$27.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$26.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.3M |
| 5 |
PA
Perceptive Advisors
New York
|
+$7.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$35.8M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$25.2M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$18.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.1M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$8.67M |
IRON Hedge Fund Activity: Q3 2023 in Review
91 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Disc Medicine (IRON) for Q3 2023, worth a combined $934M — up 10% from $849M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new IRON positions and 18 closed out — a net gain of 1 holder — while 39 added to existing stakes and 19 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $63.6M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $35.8M.
- 91 institutional investors held Disc Medicine (IRON) as of Q3 2023, up from 90 in Q2 2023.
- Funds reported $934M of Disc Medicine stock for Q3 2023, up 10% quarter-over-quarter.
- 19 funds opened new Disc Medicine positions in Q3 2023 and 18 closed out, a net change of +1 holder.
- The largest Disc Medicine buyer in Q3 2023 was Paradigm Biocapital Advisors, an estimated $63.6M added.
- The largest Disc Medicine seller in Q3 2023 was Atlas Venture Life Science Advisors, an estimated $35.8M sold.
Based on aggregated 13F filings for Q3 2023.